The combination of Src and EGFR inhibition with Gemcitabine treatment in STAT3-mediated therapy-resistant pancreatic tumors was also effective at inhibiting the growth of xenografts of both therapy-sensitive and -resistant pancreatic cancer cells in vivo without increasing toxicity[73]. This evidence concerns the gene EGFR and pancreatic neoplasm.